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Summary: The incorporation of [35S]sulfate into total and specific types of serum glyeosaminoglycans was studied in
rats with acute, subacute or chronic liver injury (liver cirrhosis), and compared with that of normal rats. The macro-
molecular (protein-bound) nature of serum glyeosaminoglycans in normal and diseased animals was also analysed.
The results show a strong increase in rate and extent of [35S]sulfate incorporation into total serum glyeosamino-
glycans for acutely but a decrease for subacutely and chronically liver damaged rats. The time-course of distribution
of label between serum chondroitin sulfate and dermatan sulfate exhibits significant changes in liver-injured animals,
in particular a relatively high proportion of dermatan [35S]sulfate in rats with cirrhotic livers.
In comparison with serum glyeosaminoglycans the labeling profile of glyeosaminoglycans in the cirrhotic liver was
quite different (heparan sulfateidermatan sulfate:chondroitin sulfate = 1:0.34:0.09) and changed only insignificantly
during a l h labeling period.
The protein-bound moiety of serum glyeosaminoglycans was not affected by liver disease; but the elution profile of
chondroitin [35S]sulfate from Dowex 1 X 2 for treated rats was altered, thus indicating a structural modification of
its carbohydrate chain.
Metabolische und strukturelle Untersuchungen der Glykosaminoglykane im Serum, im Vergleich zur Leber, bei
normalen und leber-geschädigten Ratten
Zusammenfassung: Der Einbau von [35S]Su,lfat in die gesamten und spezifischen Typen der Glykosaminoglykane im
Serum von Ratten mit akuter, subakuter oder chronischer (Lebercirrhose) Leberschädigung wurde untersucht und mit
dem gesunder Tiere verglichen. Zusätzlich würden Untersuchungen zur makromolekularen, insbesondere zur protein-
gebundenen Struktur der Glykosaminoglykane im Serum normaler und lebergeschädigter Ratten durchgeführt.
Die Ergebnisse zeigen einen starken Anstieg der Rate und des Ausmaßes der Sulfatinkorporation in die gesamten
Glykosaminoglykane im Serum bei akut, eine Erniedrigurig jedoch bei subakut und chronisch lebergeschädigten
Ratten. Der zeitliche Verlauf der Verteilung der [35S]Märkierung zwischen Chondroitinsulfat und Dermatansulfat
im Seruni ließ signifikante Veränderungen bei lebergeschädigten Tieren erkennen, insbesondere einen relativ hohen
Anteil von Dermatan [35S]sülfat bei Ratten mit Leberckrhose.
Im Vergleich zu Glykosaminoglykanen im Serum war das Markierungsprofil der Glykosaminoglykane in cirrhotischer
Leber sehr verschieden (HeparänMfat:Dermatansulfat:Chondroitinsulfat = 1:0.34:0.09) und veränderte sich während
einer l-stündigen Markierungsperiode nur geringfügig.
Die proteingebundene Struktur der Glykosaminoglykane im Serum wurde durch experimentelle Lebererkrankungen
nicht beeinflußt, jedoch weist die Änderung des Elutionsprofils von Chondroitin[35S]sulfat an Dowex l X 2 auf
strukturelle Veränderungen seiner Kohlenhydratkette bei Leberschädigung hin.
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Introduction
Previous studies on the metabolism of hepatic glycos-
aminoglycans have shown that rat liver slices synthesize
predominantly heparan sulfate and to a much smaller
degree chondroitin sulfate, hyaluronic acid and akeratan
sulfate-like fraction (1,2). Both normal and damaged
liver parenchyma, however, seem to be unable to in-
corporate[! 4C]amino sugar into dermatan sulfate
(1—3), although the latter is present in normal liver
and shows a high accumulation in injured liver tissue
(4-8).
Consequently the hypothesis was put forward that
dermatan sulfate is synthesized in extrahepatic tissues,
secreted and transported in the serum and taken up by
the liver (3, 9). Because such a metabolic pathway
would be of great importance for the pathogenesis of
the fibrotic transition of chronically injured liver
tissue, we studied the metabolism of total and specific
types of sulfated glycosaminoglycans in serum of normal
and liver-injured rats, compared it with that in liver.
In addition, we investigated the structure of the macro-
molecular, in particular protein-bound nature of serum
glycosaminoglycans.
Materials and Methods
Materials
Chondroitin AC (EC 4.2.2.5) and ABC (EC 4.2.2.4) lyases were
obtained from Seikagaku Kogyo Comp., Tokyo, Japan; papain
(EC 3.4.22.2, crystalline suspension, 30 U/mg protein) was from
Boehringer Mannheim GmbH, Germany; thioacetamide p.a. was
from Merck AG, Darmstadt, Germany ;D-[l-14C]glucosamine
hydrochloride (288.6 GBq/mol) and sodium [3SS]sulfate
(carrier free) were from New England Nuclear Corp., Boston,
USA; Sephadex G-100 and Sepharose CL-4B were from
Pharmacia, Uppsala, Sweden; Dowex 1 X 2 and Bio-Gel P 2
were from BioRad Laboratories, Munich, Germany.
Treatment of rats
Male Sprague-Dawley rats (250-320 gs Zentralinstitut fur Ver^
suchstiere, Hannover, FRG) received food and water ad libitum.
Acute liver injury was induced by two repeated intraperitoneal
thioacetamide injections of 100 mg/kg in a 24 h interval. One
day after the last injection the rats were sacrificed. Subacute
and chronic liver injury was produced by oral administration of
thioacetamide for 4 weeks and 10 months, respectively, as
described previously (2).
In general, each value represents the mean of two to four in-
dependent experiments. .
Determination of the incorporation of isotopes into total
glycosaminoglycans of serum
Rats were injected intraperitoneally with either 37 MBq of
sodium [35Slsulfate or 1.3 MBq of [ 14C]glucosamine hydro-
chloride and decapitated at various times thereafter. 1-2 ml of
blood was collected from the neck vessels and non-hemolytic
serum produced. The serum proteins were precipitated by
addition of 5 vol. of acetone, centrifuged for 5 min at 3000 £
and delipidized by washing consecutively with 5 vol. of ace-
tone, chloroform-methanol (volumes, 200 ml + 100 ml) and
ethanol-ether (volumes, 300 ml + 100 ml). The final sediment
was dried at 60 °C, homogenized in 3 ml of papain-buffer (10)
from which an aliquot was taken for the determination of
protein (11) and proteolysed for 24 h by the addition of 300 μ\
(90 U) of papain (1). Total glycosaminoglycans were isolated
from the proteolysate (1), dissolved in water and an aliquot
was taken for the determination of [14C]-or[35S]-radioactivity
in a liquid scintillation spectrometer with an efficiency of 81%.
Determination of the incorporation of isotopes into total
glycosaminoglycans of liver
After injection of the isotope the liver was quickly removed,
chilled and minced in ice-cold buffer (0.05 mol/1 tris-HCl,
pH 7.6 (20 °C), 0.08 mol/1 KC1, 0.0125 mol/1 MgCl2), freed
carefully of blood and homogenized at 2 °C. The protein was
precipitated with 5 vol. of acetone and defatted and proteo-
lysed as above. Glycosaminogly can-associated radioactivity .was
isolated and counted as described for serum.
Determination of the incorporation of isotopes into specific
types of glycosaminoglycans of serum and liver
As described elsewhere (1) total glycosaminoglycans were
subjected to enzymatic analysis with chondroitin ABC and AC
lyases to determine the incorporation of label into chondroitin
sulfate and dermatan sulfate, and degraded by nitrous acid to
quantitate the incorporation into heparan sulfate and heparin.
The incorporation of radioactivity into specific types of
glycosaminoglycans was expressed as percentage of the activity
of the unfractionated glycosaminoglycans.
Total labeled glycosaminoglycans of serum were chromato*
graphed on a column (0.6 X 13 cm) of Dowex 1 X 2 (CD by
stepwise elution with an increasing molarity of NaCl (1,12).
The fractions were dialyzed, dried, dissolved in water and sub-
jected to enzymatic and chemical identification.
Gel chromatography of serum glycosaminoglycans
13 ml of serum from normal rats, which received [^5S]sulfate
5 h prior to decapitation, were applied to a column (1.4 X 60
cm) of Bio-Gel P 2 and eluted with high ionic strength buffer A
(0.02 mol/1 Tris-HCl, pH 7.6 (20 °C), 0.5 mol/1 KC1, 0.003
mol/1 MgClj). The excluded radioactivity was concentrated by
ultrafiltration (filter UM 2, Amicon GmbH) and rechromato-
graphed on a column (2 X 120 cm) of Sepharose CL-4B. The
activity eluted with buffer A between 300 and 325 ml was
pooled, dialyzed and divided in two equal portions. One portion
wasrechiomatographed on a column (2 X 120 cm) of Sephadex
G-100 after proteolytic digestion with 200 μΐ (60 U) of papain
for 48 h at 60 °C, the other one was treated identically but
without addition of papain. The eluates were fractionated into
5 ml portions and analysed foi radioactivity. All Chromato-
graphie procedures were performed at 4 °C.
Density gradient centrifugation of serum glycosaminogiycans
The undigested radioactive material eluted with buffer A
between 125 and 150 ml from Sephadex G-100 was concen-
trated by ultrafiltration (filter PM 10) and adjusted to a starting
density of 1.55 kg/i by the addition of solid CsCl2. The gradients
(13 ml) were centrifuged for 60 h at 155 000£ and 20 °C and
then fractionated into 1 ml portions in which the density and
radioactivity were determined. The fraction containing the peak
activity was proteolysed and subjected to enzymatic analysis for
chondroitin sulfate.
Electrophoresisof[3SS]-Iabeled serum components
Serum was obtained from normal rats which recived [3SS]-
sulfate 5 h before exitus. The proteins were separated by
cellulose acetate foil electrophoresis following standard clinical
laboratory procedures (13). The bands of more than 20 electro-
pherograms were cut out, pooled arid counted for radioactivity
after addition of Instagel (Packard).
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Results
Labeling pattern of specific glycosaminoglycans in liver
and serum
As previously reported (1,2) rat liver explants do not in-
corporate [14C]hexosamine and only a very small
fraction of [35S] sulfate (0.007-0.013 of total glycos-
aminoglycans) into dermatan sulfate. The data shown
in table 1 confirm the inability of rat liver to incorporate
[14C]hexosamine into dermatan sulfate in vivo during
a l h labeling period. However, using [35S] sulfate as a
precursor a fraction of about 0.15 of the total glycos-
aminoglycan radioactivity was found in dermatan sulfate.
Both isotopes were incorporated predominantly into
heparan sulfate (0.70 to 0.85) the remainder being
recovered in chondroitin sulfate (tab. 1).
The proportions did not change significantly in acutely
injured liver (data not shown).
In serum of normal and liver-damaged rats [14C]-
gjucosamine was incorporated exclusively into chon-
droitin sulfate. This type of serum giycosaminoglycan
was also predominantly labeled after injection of
[3SS]sulfate. Only a small fraction of [35S]label was
found in serum dermatan sulfate and heparan sulfate
(tab. 1).
Time course of[3SS]sulfate incorporation into serum
glycosaminoglycans of normal and liver-damaged rats
Only [35S]sulfate is incorporated both into liver and
serum dermatan sulfate. Consequently this type of
isotopic precursor was used in the following studies.
[35S] sulfate is incorporated very rapidly into serum
glycosaminoglycans of normal rats (fig. 1). Nearly a frac-
tion of 0.50 of the final radioactivity of serum glycos-
aminoglycans (at 300 min) is reached within 45 min
after application of the isotope.
Tab. 1. The pattern of incorporation of [14C]glucpsainine and
[^SS] sulfate into specific types 9f glycosaminoglycans in
liver and serum of normal rats. Rats received the isotopes
l h before sacrifice. Giycosamiiioglycans isolated from
liver and serum were characterized by enzymatic and
chemical procedures. The radioactivity incorporated into
specific types is expressed as fraction of total glycosamiho-
glycan-radioactivity. The ratios are the mean of triplicate
experiments.
Isotopic
precursor
Liver
[14C)Glucpsamine
Serum
Liver
[3sS]Sulfate
Serum
Heparan
sulfate *
0.856
-
0.725
0.044
Chondroitin
sulfate
0.123
1.00
0.042
0.85
Dermatan
sulfate
—
.-
0.152
0.065
20
15
|MO
I
15 30 60 120
t i m i n )
300
Fig. 1. Time course of [3S S ] sulfate incorporation into total
serum glycosaminoglycans of normal (· ·), acutely
(o o), subacutely (Δ Δ) and chronically (A A)
liver-injured rats.
The animals were sacrificed at various times after injection
of the isotope, and the radioactivity incorporated into
total serum glycosaminoglycans was determined and re-
ferred to the concentration of serum protein. The total
serum protein concentration did not change under treat-
ment.
Rate and extent of incorporation of sulfate into glycos-
aminoglycans are significantly augmented in acutely
liver-damaged rats. 5 h after application of the isotope
the activity of total serum glycosaminoglycans was over
4 times higher than normal (fig. 1).
In contrast, long- und middle-term liver damage
resulted in a 30% and 75% reduction of the respective
final activities of serum glycosaminoglycans (fig. 1).
The differences in the kinetics of sulfate incorporation
into serum glycosaminoglycans of rats in different
stages of liver injury become more complex if the time-
dependency of the labeling pattern of specific types of
glycosaminoglycans is analysed (fig. 2). In normal rats
a fraction of 0.65 of the sulfate incorporated within
15 min into serum glycosaminoglycans was found in
chondroitin sulfate, the remainder being associated
with dermatan sulfate. Concomitantly with a further
time-dependent increase in the fraction of chondroitin
[3*S] sulfate, the dermatan[3SS]sulfate disappears within
2 h from the circulation (fig. 2 a). No other sulfated
glycosaminoglycans could be detected in.serum in
significant amounts.
In rats with acute liver injury the proportion of initially
'[3SS]labeled chondroitin sulfate was higher (0.81) where-
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Fig. 2. Time course of the relative incorporation of [3S S J sulfate
into specific types of serum glycosaminoglycans of normal
(a), acutely (b), subacutely (c) and chronically (d) liver-
injured rats: The animals were treated as described in
fig. 1, individual glycosaminoglycans were identified by
chemical and enzymatic procedures and expressed as a
fraction of total glycosaminoglycans. Chondroitin sulfate
• ·, dermatan sulfate ο ο.
as that of dermatan sulfate was lower (about 0.10) than
normal. During a 5 h period the relative distribution did
not change significantly (fig. 2b).
In animals with subacute and chronic liver damage the
initial sulfation pattern was reversed, i.e. the fraction
of labeled dermatan sulfate was greater than that of
chondroitin sulfate (fig. 2c, d). In long-term liver-
injured rats a fraction of 0.82 of [35S] sulfate incorpor-
ated into total glycosaminoglycans was found initially
(at 15 min) in dermatan sulfate, the remainder in chon-
droitin sulfate (fig. 2D). Since the fraction of circulating
[35S] dermatan sulfate declines more owly in rats with
chronic liver damage than in untreated animals, their
relative level of serum dermatan[35S] sulfate was found
to be significantly elevated.
Time course of [3* S]sulfate incorporation into liver
glycosaminoglycans
The kinetics of sulfation of glycosaminogjycans in
serum was studied in comparison to that in liver of
injured rats. Figure 3 a demonstrates a highly active
sulfation of glycosaminoglycans in liver which is detect-
able as early as 2 min after application of the isotope.
In contrast, the sulfation of glycosaminoglycans in
1—2 ml of serum (protein concentration about 70 g/1)
was not detectable until 10 min after injection of the
label. At this time the activity (Bq/mg protein) of total
glycosaminoglycans in the liver was about 125 times
higher than in serum (tab. 2).
Tab. 2. Ratio of incorporation of [3δ S ] sulfate into glycosamino-
glycans of liver and serum of chronically liver-damaged
rats. The calculation is based on the data given in fig. 3.
The activity of glycosaminoglycans is expressed per mg
of protein of liver or serum, respectively.
Time Liver/serum ratios of radioactivity
after application (Bq/mg protein)
of [3SS]sulfate incorporated into glycosaminoglycans
(min)
10
15
30
60
Total
127
63
42
74
Chondroitin
sulfate
26
6
2
Dermatan
sulfate
16
24
45
5 10 20
Fig. 3. Time course of [35S]sulfate incorporation into total and specific types of glycosaminoglycans in liver and serum of chronically
injured rats. The animals were injected with 18 MBq of [3*S] sulfate and decapitated at the times indicated. The radioactivity
incorporated into total glycosaminoglycans (a) of serum (· ·) and liver (c- o) was determined/The incorporation into
specific glycosaminoglycans of liver (b, ο ο heparan sulfate, · · dermatan sulfate, · · chondroitin sulfate) and serum
(c, ο ο dermatan sulfate, · · chondrotin sulfate) is expressed as a fraction of the incorporation into total glycosamino
glycans.
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As illustrated in figure 3b and c the time courses of
sulfation of individual glycosaminoglycans in liver and
serum of chronically liver-injured rats are strikingly
different. The ratios of incorporation of [3SS] sulfate
into heparan sulfate, dermatan sulfate and chondroitin
sulfate of liver were 1:0.34:0.09 and remained nearly
unchanged with time. In serum, however, the relative
distribution of [3SS] sulfate between chondroitin sulfate
and dermatan sulfate reversed with time (fig. 2d, 3c).
The ratios of sulfation of liver- and serum-derived der-
matan sulfate and chondroitin sulfate were calculated.
The data summarized in table 2 indicate a much higher
incorporation of sulfate into the glycosaminoglycan
types of liver at any time. The liver/serum ratios
exhibit a time-dependent increase for dermatan sulfate
but a decrease for chondroitin sulfate.
Proteoglycan character of serum glycosaminoglycans
Results presented above demonstrate metabolic changes
of serum glycosaminoglycans in rats with experimental
liver injury. Further studies were performed to analyse
the macromolecular and protein-bound nature of serum
glycosaminoglycans and its possible alteration in liver-
damaged animals.
Figure 4 shows that the peak [35S] sulfate activity in-
corporated into serum components comigrates with the
ax -globulin fraction regardless of the origin of the serum,
i.e. from healthy or liver-damaged rats.
Albumin
Globulins
Fig. 4. Cellulose acetate foil eleetrophoresis of l35S]-labeled
components from rat serum. 5 h after i.p. injection of
13SS] sulfate into a normal rat, blood was collected and
about 50 μΐ-of serum electrophoretically separated. The
protein fractions of about 20 electrophoreses were cut
out and their radioactivity (o-r^-o) determined. A typical
densitpgraph ( ) is illustrated. Essentially identical
results were obtained with serum from liver-injured rats
(not shown).
However, it is by no means certain that some if any of the
activity of the at-globulin is proteoglycan in nature.
Therefore serum obtained from normal rats injected
previously with [35S] sulfate was chromatographed on
Bio-Gel P2 to remove low molecular weight [35S]sulfate
labeled components (fig. 5). The excluded radioactivity
was rechromatqgraphed on Sepharose CL-4B. The frac-
tions which contained chondroitin [35S]sulfate (Kav
= 0.76) were further chromatographed on a column of
Sephadex G-100 before (fig. 5c) and after (fig. 5d)
proteolysis by papain. Extensive degradation to low
100 200 300
Effluent volume [ml]
400
Fig. 5. Gel chromatography of [3SS]labeled glycosaminoglycans
from normal rat serum.
The animals were decapitated 5 h after injection of
[3SSJ sulfate and blood was collected. 13 ml of serum was
applied to a column of Biogel P 2 and eluted with buffer A
(0.02 mol/1 Tris-HCl, pH 7.6, 0.5 mol/1 KC1, 0.003 mol/1
MgCl2). The activity eluted between 50 and 70 ml (a) was
lechromatographed on a column of sepharose CL - 4 B in
buffer A (b). The fractions between 300 and 325 ml
effluent were pooled and divided in two equal portions
(a and b). Portion a was digested with papain prior to
chromatography on Sephadex G 100 (d); portion b was
treated identically but without addition of papain (c).
The inset in c represents the distribution of the undigested
chondroitin sulfate in 13 ml of a CsCl-density gradient
(· ·, density).
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molecular weight fractions was observed after proteo-
lytic treatment. The elution pattern of the undegraded
chondroitin sulfate (Kav = 0.05) (fig. 5c) and degraded
chondroitin sulfate (Kav = 0.55) (fig. 5d) was not
changed by the addition of excessive amounts of un-
labeled chondroitin sulfate and rat serum protein,
respectively. It should be emphasized that after proteo-
lysis a major radioactive peak of unknown identity
occurred at Vt (380 ml) of Sephadex G-100 (fig. 5 d).
The high molecular weight fraction of serum glycos-
aminoglycans, which was almost excluded from
Sephadex G-100 (fig. 5c), was further characterized
by isopycnic density gradient centrifugation under
both associating and dissociating conditions (in the
presence of 4 mol/1 of guanidinium hydrochloride).
In each case a fraction of about 0.90 of the total
chondroitin sulfate banded near the top of the gradient
at a density of d = 1.44 kg/1 (inset in fig. 5 c). Neither
the gel Chromatographie elution pattern of serum
glycosaminoglycans nor their distribution in iso-
pycnic gradients showed any change under the influence
of liver injury (results not shown).
However, differences were observed in the ion-exchange
Chromatographie behaviour of [35S] glycosaminoglycans
from serum of normal and acutely liver-injured rats.
[35S] labeled chondroitin sulfate from treated rats
tended to elute at lower ionic strength (0.5 mol/1
NaCl) from Dowex 1 X 2 than the glycosaminoglycans
isolated from normal rat serum (fig. 6).
0.70
0.60
g 0.50
t, 0.40
I 0.30
£
0.20
0.10 I
0.15 0.5 1.0 1.25 1.5 2.0 35' *
NaCl [mol/l]
Fig. 6. Anion-exchange chromatography of [3SS]-labeled glycos-
aminoglycans from serum of normal (open bars) and
acutely liver-injured (hatched bars) rats.
The animals were decapitated 5 h after injection of
[35S] sulfate. Total glycosaminoglycans (containing pre-
dominantly chondroitin sulfate) were isolated from
serum, applied to a column of Dowex 1 X 2 and eluted
with a stepwise gradient of increasing molarity of NaCl.
Fractions were assayed for radioactivity.
Discussion
Although distribution and chemical composition of
acidic glycosaminoglycans in blood have been reported
by several investigators (14-21) detailed information
on their physiological functions, metabolism and patho-
biochemical alterations are still lacking. It has been
reported that human serum contains a preponderance
of undersulfated chondroitin 4-sulfate and chondroitin
6-sulfate (21-23) and only a small amount of chon-
droitinase-resistant acidic glycosaminoglycans (heparan
sulfate, dermatan sulfate, keratan sulfate) (20-22).
Accordingly, we observed in normal rats a nearly ex-
elusive incorporation of [35S] sulfate and [l4C]glucos-
amine into chondroitin sulfate. The source of serum
glycosaminoglycans is unknown but it was suggested
that they may derive at least in part from leukocytes
or platelets (21,23—25) or orginate from the extra-
cellular matrices of various tissues. The sites of degra-
dation (e.g. desulfation) of the different types of serum
glycosaminoglycans are also not known but obviously
glycosaminoglycan-degrading tissues are widespread in
the body (26). Several studies indicate that the liver
might have an important function in this process (26,27).
Information on the concentration, composition and
metabolism of glycosaminoglycans in serum of patients
with liver disease or in serum of experimentally liver-
injured rats is lacking. But from the increase of the
urinary excretion of glycosaminoglycans in patients
with chronic hepatitis or florid cirrhosis (28) con-
comitant alterations of the concentration and compo-
sition of glycosaminoglycans in serum can be deduced.
Further studies are necessary to prove such changes and
to elucidate their role in the pathogenesis of liver fibrosis,
Slices of normal and injured liver do not incorporate
[14C]hexosamine and far less than a fraction of 0.01 of
[35S] sulfate into dermatan sulfate (1,2, 29). It might
be possible that an as yet unidentified extrahepatic
factor which promotes specifically the synthesis or
sulfation of dermatan sulfate in liver is lacking in vitro,
but it also seems likely that hepatic dermatan sulfate is
supplied to the liver from extrahepatic sources. The
present results indirectly support this assumption, since
in vivo a fraction of about 0.15 of total liver [3sS]glycos-
aminoglycan activity is located in dermatan sulfate;
also significant changes of the kinetics of sulfation
of serum dermatan sulfate occur in chronically liver-
injured rats, and the liver/serum ratio of dermatan
[35S] sulfate increases with time nearly 3-fold,
whereas that of chondroitin sulfate and of total gjycos-
aminogjycan declines (tab. 2). However, the specificity
of these serum changes for liver injury remains to be
deterihiried. From the data given in figure 3 the
amount of labeled dermatan sulfate in the whole liver
and in the total serum volume of a rat (320 g body
wt.) can be calculated, based on a rat plasma volume
of 39 ml/kg body weight (30), a serum protein con*
J: Clin. Chem. Clin. Biochem. / Vol. 18, 1980 / No. 5
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centration of 70 g/1 and a total liver protein of 1.1 g.
Accordingly 15, 30 and 60min after injection of [35S]-
sulfate the respective total amounts of dermätan [35S]-
sulfate in the liver are 20-, 30-, and 57-fold, greater than
in the whole body serum. This indicates that either
serum dermatan sulfate cannot be the single source of
liver dermatan sulfate or that dermatan sulfate coming
from the serum is rapidly sulfated in the liver. Since
neither liver — nor serum — dermatan sulfate incorpor-
ated [14C]hexosamine, its sulfate groups must turn over
more rapidly than, and independently from, the carbo-
hydrate chain. Thus incorporation of sulfate in this type
of glycosaminoglycan does not represent "de novo"
synthesis, but sulfation of an already existing carbo-
hydrate acceptor.
The experimental evidence for a supply of the carbo-
hydrate chain acceptor to the liver via the systemic
circulation, as suggested here, is rather circumstantial.
Studies on the uptake and deposition of proteodermatan
sulfate in normal and diseased liver, where it cannot be
degraded by lysosomal enzymes (31, 32), are difficult
at present, because homologous liver or serum proteo-
dermatan sulfate is not available in amounts sufficient
for intravenous injections or application to the medium
of isolated perfused rat livers. The use of a glycosamino-
glycan instead of native proteoglycan for such studies
might lead to erroneous results since the metabolism
of both types is quite different if injected intravenously
(33,34). y
In the present study the macromolecular nature of
serum glycosaminoglycans was shown, which con-
firms the results of earlier reports (20, 21, 23, 35).
Although glycosaminoglycans can interact electro-
statically with a number of serum proteins (36)
a covalent linkage to protein (core protein) seems
likely since chondroitin sulfate radioactivity could not
be displaced from protein by high amounts of the
unlabeled counterpart (fig. 5c). Furthermore, the re-
addition of serum protein to the glycosaminoglycan
obtained after proteolysis was without effect on their
gel Chromatographie elution pattern (fig. 5 d). The
large amount of low molecular weight [35S] labeled
material liberated by proteolysis (eluting at Vt, fig.
5d) was not characterized further. It might partially
originate from [35S]sulfate entrapped by undegraded
serum proteins, although chromatography was per-
formed in buffers of high ionic strength. The material,
however, might also derive from [35S] containing oligo-
saccharides covalently linked to serum proteins. It is
noteworthy that liver damage does not affect the
macromolecular composition of serum glycosamino-
glycans, but some changes in the carbohydrate chain
occur as indicated by the differences in the ion ex-
change Chromatographie elution profiles (fig. 6).
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